IGC Pharma Inc
IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimerβs disease. The Companyβs flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimerβs by targeting AΞ² plaques, a key disease hallmark. The Companyβs IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting AΞ² plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimerβs disease, including AΞ² plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying IGC Pharma's stock, expecting its value to rise significantly.
Financial Health
IGC Pharma is generating modest revenue and some cash flow, but its overall financial position is average.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IGC
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: October 14, 2025
Explore BasketWhy Youβll Want to Watch This Stock
Microcap market dynamics
A market cap near $36m can provide meaningful upside if milestones are hit, though expect higher volatility and reduced liquidity compared with larger stocks.
R&D catalysts and trials
Clinical or regulatory progress tends to be a primary value driver for pharma firms; outcomes are often binary and can move the share price sharply.
Funding and partnerships
Smaller pharmaceutical companies commonly rely on partnerships or capital raises to advance programmes, which can dilute holders but also deβrisk development if done strategically.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
